SiPhox Health, a LongeVC portfolio company, is making at-home blood testing more accessible and user-friendly. By leveraging silicon photonics, SiPhox offers a simple and painless method to track up to 50 biomarkers, providing lab-quality results without the need for traditional diagnostics. This technology enables early detection of conditions like cardiovascular disease, diabetes, and hormonal imbalances, promoting better health outcomes through convenient and regular testing.
LongeVC is pleased to continue supporting SiPhox in their A2 funding round. The company has shown impressive growth, doubling its revenue in 2024 and expanding to a team of 45 employees by early 2025. SiPhox's advancements in product development, workflow optimization, and R&D highlight its leadership in the at-home diagnostics market.
Recently, SiPhox co-founder and CPO, Michael Dubrovsky, shared insights into the company's impact on at-home testing during an interview at SiliconANGLE & theCUBE studio at NYSE. You can watch the interview here.
For more information about SiPhox Health’s innovative approach to consumer diagnostics, visit their website here.
LongeVC is pleased to continue supporting SiPhox in their A2 funding round. The company has shown impressive growth, doubling its revenue in 2024 and expanding to a team of 45 employees by early 2025. SiPhox's advancements in product development, workflow optimization, and R&D highlight its leadership in the at-home diagnostics market.
Recently, SiPhox co-founder and CPO, Michael Dubrovsky, shared insights into the company's impact on at-home testing during an interview at SiliconANGLE & theCUBE studio at NYSE. You can watch the interview here.
For more information about SiPhox Health’s innovative approach to consumer diagnostics, visit their website here.